Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Novel Clinical Trial in Rare Paediatric B-Cell Non-Hodgkin Lymphoma: Evaluating the Glo-Bnhl Adaptive Bayesian Design Using Data from the Sparkle Trial

Shanna Maycock, Rui Qin, Emma Seaford, Anna Lawson, Ellie Williams, Joseph Rogers, Zahra Ahmed, Mahnoor Muzaffar, Rhianna Parsons, Sanjay Deshpande, Gladstone Austin Amos Burke, Lucinda Billingham

Blood (2024) 144 (Supplement 1): 6490.

https://doi.org/10.1182/blood-2024-204787

Published: 2024

Journal Articles

Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting

Jose Angel Hernandez-Rivas, Pier Luigi Zinzani, Mats Jerkeman, Malalatiana Be Harvel, Suzy Van Sanden, Joris Diels, Asad Husain, Christoph Tapprich, Sanjay Deshpande, Steven Le Gouill, Martin Dreyling

Blood (2022) 140 (Supplement 1): 3648–3650.

https://doi.org/10.1182/blood-2022-158259

Published: 2022

Journal Articles

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Simon Rule, Martin H. Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MRCP, FRPath, PhD, Brad S. Kahl, MD, Jose Angel Hernandez-Rivas, MD PhD, Keqin Qi, PhD, Sanjay Deshpande, Lori Parisi, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 1538.

https://doi.org/10.1182/blood-2019-124691

Published: 2019

Journal Articles

Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial

Sriram Balasubramanian, Brendan Hodkinson, Stephen J. Schuster, MD, Nathan H. Fowler, MD, Judith Trotman, Georg Hess, Bruce Cheson, MD, Michael Schaffer, PhD, Shean-Sheng Wang, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, MD PhD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 4147.

https://doi.org/10.1182/blood-2018-99-116472

Published: 2018

Journal Articles

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Simon Rule, MD, Martin Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MD PhD, Brad S Kahl, MD, Jose Angel Hernandez-Rivas, Anil Londhe, PhD, Fong Clow, ScD, Sanjay Deshpande, Lori Parisi, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 151.

https://doi.org/10.1182/blood.V130.Suppl_1.151.151

Published: 2017

Journal Articles

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Gilles A. Salles, Judith Trotman, MB ChB, Michael Lill, MD BS, Bruce Cheson, MD, Stephen J. Schuster, MD, Jing-Zhou Hou, John A Radford, MB ChB, MRCP, MD FRCP, Andrew Spencer, Michael Schaffer, PhD, Rajendra Damle, PhD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Sanjay Deshpande, MD, Dolores Caballero, MD PhD

Blood (2016) 128 (22): 2980.

https://doi.org/10.1182/blood.V128.22.2980.2980

Published: 2016

Journal Articles

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Ajay K. Gopal, MD, Stephen J. Schuster, MD, Nathan Fowler, MD, Judith Trotman, MBChB, Georg Hess, MD, Jing-Zhou Hou, Abdulraheem Yacoub, MD, Michael Lill, MD BS, Peter Martin, MD, Umberto Vitolo, MD, Wojciech Jurczak, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, Dzhelil Osmanov, MD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Shean-sheng Wang, PhD, Sanjay Deshpande, MD, Gilles A. Salles

Blood (2016) 128 (22): 1217.

https://doi.org/10.1182/blood.V128.22.1217.1217

Published: 2016

NARROW

A Novel Clinical Trial in Rare Paediatric B-Cell Non-Hodgkin Lymphoma: Evaluating the Glo-Bnhl Adaptive Bayesian Design Using Data from the Sparkle Trial

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Email alerts

ASH Publications

American Society of Hematology

A Novel Clinical Trial in Rare Paediatric B-Cell Non-Hodgkin Lymphoma: Evaluating the Glo-Bnhl Adaptive Bayesian Design Using Data from the Sparkle Trial

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only